4.7 Article

Monosomal karyotype in primary myelofibrosis is detrimental to both overall and leukemia-free survival

Journal

BLOOD
Volume 117, Issue 21, Pages 5612-5615

Publisher

AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2010-11-320002

Keywords

-

Categories

Ask authors/readers for more resources

Survival in cytogenetically high-risk patients with acute myeloid leukemia or myelodysplastic syndromes is significantly worse in the presence of a monosomal karyotype (MK). The objective of the present study was to determine whether the same held true for primary myelofibrosis. Among 793 primary myelofibrosis patients seen at our institution, 62 displayed an unfavorable karyotype by way of complex karyotype (n = 41) or sole trisomy 8 (n = 21). Seventeen (41%) of the 41 patients with complex karyotype were classified as having an MK. Median survival was 6, 24, and 20 months in patients with MK, complex karyotype without monosomies, and sole trisomy 8, respectively (P<.0001). The corresponding 2-year leukemic transformation rates were 29.4%, 8.3%, and 0 (P<.0001); hazard ratios (95% confidence intervals) were 6.9 (1.3-37.3) and 14.8 (1.7-130.8). The prognostic relevance of MK was not accounted for by the Dynamic International Prognostic Scoring System. We conclude that MK in primary myelofibrosis is associated with extremely poor overall and leukemia-free survival. (Blood. 2011; 117(21): 5612-5615)

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Oncology

The influence of disease and comorbidity risk assessments on the survival of MDS and oligoblastic AML patients treated with 5-azacitidine: A retrospective analysis in ten centers of the Rete Ematologica Lombarda

Alfredo Molteni, Marta Riva, Lorenza Borin, Massimo Bernardi, Anna Maria Pelizzari, Alessandra Freyrie, Matteo Della Porta, Michele Nichelatti, Emanuele Ravano, Giulia Quaresmini, Jacopo Mariotti, Domenica Caramazza, Marta Ubezio, Simona Guarco, Federica Gigli, Rosa Greco, Roberto Cairoli, Enrica Morra

LEUKEMIA RESEARCH (2016)

Article Hematology

It is time to change thrombosis risk assessment for PV and ET?

Francesco Passamonti, Domenica Caramazza, Barbara Mora, Rosario Casalone, Margherita Maffioli

BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2014)

Article Hematology

Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls

Srdan Verstovsek, Hagop M. Kantarjian, Zeev Estrov, Jorge E. Cortes, Deborah A. Thomas, Tapan Kadia, Sherry Pierce, Elias Jabbour, Gautham Borthakur, Elisa Rumi, Ester Pungolino, Enrica Morra, Domenica Caramazza, Mario Cazzola, Francesco Passamonti

BLOOD (2012)

Article Hematology

Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts

Francesco Passamonti, Margherita Maffioli, Francisco Cervantes, Alessandro Maria Vannucchi, Enrica Morra, Tiziano Barbui, Domenica Caramazza, Lisa Pieri, Elisa Rumi, Heinz Gisslinger, Laurent Knoops, Jean Jaques Kiladjian, Barbara Mora, Norbert Hollaender, Cristiana Pascutto, Claire Harrison, Mario Cazzola

BLOOD (2014)

Review Hematology

New generation small-molecule inhibitors in myeloproliferative neoplasms

Francesco Passamonti, Margherita Maffioli, Domenica Caramazza

CURRENT OPINION IN HEMATOLOGY (2012)

Article Oncology

Clinical Predictors of Outcome in MPN

Francesco Passamonti, Margherita Maffioli, Michele Merli, Andrea Ferrario, Domenica Caramazza

HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2012)

Article Oncology

DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status

Naseema Gangat, Domenica Caramazza, Rakhee Vaidya, Geeta George, Kebede Begna, Susan Schwager, Daniel Van Dyke, Curtis Hanson, Wenting Wu, Animesh Pardanani, Francisco Cervantes, Francesco Passamonti, Ayalew Tefferi

JOURNAL OF CLINICAL ONCOLOGY (2011)

Article Oncology

Circulating Interleukin (IL)-8, IL-2R, IL-12, and IL-15 Levels Are Independently Prognostic in Primary Myelofibrosis: A Comprehensive Cytokine Profiling Study

Ayalew Tefferi, Rakhee Vaidya, Domenica Caramazza, Christy Finke, Terra Lasho, Animesh Pardanani

JOURNAL OF CLINICAL ONCOLOGY (2011)

Letter Oncology

Leukemia risk models in primary myelofibrosis: an International Working Group study

A. Tefferi, A. Pardanani, N. Gangat, K. H. Begna, C. A. Hanson, D. L. Van Dyke, D. Caramazza, A. M. Vannucchi, E. Morra, M. Cazzola, A. Pereira, F. Cervantes, F. Passamonti

LEUKEMIA (2012)

Letter Oncology

Looking for CALR mutations in familial myeloproliferative neoplasms

M. Maffioli, A. Genoni, D. Caramazza, B. Mora, A. Bussini, M. Merli, T. Giorgino, R. Casalone, F. Passamonti

LEUKEMIA (2014)

Article Oncology

CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons

A. Tefferi, T. L. Lasho, C. M. Finke, R. A. Knudson, R. Ketterling, C. H. Hanson, M. Maffioli, D. Caramazza, F. Passamonti, A. Pardanani

LEUKEMIA (2014)

Article Hematology

Cerebral venous thrombosis and myeloproliferative neoplasms: Results from two large databases

Francesco Dentali, Walter Ageno, Elisa Rumi, Ilaria Casetti, Daniela Poli, Umberto Scoditti, Margherita Maffioli, Matteo Nicola Dario di Minno, Domenica Caramazza, Daniela Pietra, Valerio De Stefano, Francesco Passamonti

THROMBOSIS RESEARCH (2014)

Letter Medicine, General & Internal

JAK Inhibitor in CALR-Mutant Myelofibrosis

Francesco Passamonti, Domenica Caramazza, Margherita Maffioli

NEW ENGLAND JOURNAL OF MEDICINE (2014)

Review Hematology

Novel agents in indolent lymphomas

Michele Merli, Andrea Ferrario, Claudia Basilico, Margherita Maffioli, Domenica Caramazza, Lorena Appio, Luca Arcaini, Francesco Passamonti

THERAPEUTIC ADVANCES IN HEMATOLOGY (2013)

Article Oncology

Myeloproliferative neoplasms: From JAK2 mutations discovery to JAK2 inhibitor therapies

Francesco Passamonti, Margherita Maffioli, Domenica Caramazza, Mario Cazzola

ONCOTARGET (2011)

No Data Available